Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics


Manage episode 303360642 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the use of newer cytotoxic strategies, targeted agents, epigenetic modifiers, and antibody-based treatment. Upon completion of this accredited CE activity, participants should be better able to: Describe factors for prognostic assessment and selection of treatment for patients with AML, including a diagnosis of CBF-AML; secondary AML; or AML with intermediate cytogenetics or TP53, FLT3, and/or IDH mutations, Summarize updated clinical evidence surrounding the use of novel cytotoxic, antibody, epigenetic, or targeted strategies, including novel combination strategies, for a range of AML patient populations and treatment settings, including upfront and post-remission therapy or in the management of relapsed/refractory AML, Design a personalized treatment plan for patients with newly diagnosed or relapsed/refractory AML who present with favorable, intermediate, or poor prognostic factors, Develop management protocols for unique adverse events associated with the use of novel therapeutics for AML.

306 episodes